Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Canadian Journal of Physiology and Pharmacology|April 1, 1989
Effect of rat cardionatrin I (rat ANF 99-126) on the response of toad skin to angiotensin IIA Coviello, M O Soria, M C Proto, et al.
Comparative Biochemistry and Physiology. Comparative Physiology|January 1, 1993
Effects of angiotensin I of the American bullfrog Rana catesbeiana on amphibian tissuesA Coviello, M O Soria, M C Proto, et al.
Gynecologic and Obstetric Investigation|January 1, 1990
Growth hormone and somatomedin-C secretion in patients with polycystic ovarian disease. Their relationships with hyperinsulinism and hyperandrogenismA Lanzone, A M Fulghesu, S Pappalardo, et al.
International Journal of Cancer|May 30, 2009
Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colonAntonietta Santoro, Simona Pisanti, Claudia Grimaldi, et al.
Genes, Brain, and Behavior|August 8, 2009
Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effectsP Monteleone, M Bifulco, C Di Filippo, et al.
Minerva Endocrinologica|December 9, 1998
IGF-I levels in prepubertal and pubertal children with Down syndromeL Ragusa, M R Valetto, C Proto, et al.
Cancer Treatment Reviews|November 19, 2025
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategiesD Miliziano, C Sciortino, S Manglaviti, et al.
ESMO Real World Data and Digital Oncology|April 3, 2026
Corrigendum to "Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of <i>EGFR</i>-mutated advanced NSCLC patients": [ESMO Real World Data and Digital Oncology Volume 10, December 2025, 100198]F Corso, P Baili, F Scotti, et al.
Cancer Treatment Reviews|April 8, 2019
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave outC Proto, R Ferrara, D Signorelli, et al.
ESMO Open|December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkersG Lo Russo, F Sgambelluri, A Prelaj, et al.
Pageof 5